Entity: GLP-1 drugs
📊 Facts Database / Entities / GLP-1 drugs

GLP-1 drugs

2 Facts
3 Related Topics
A 2025 KFF analysis identified main drivers of recent ACA premium increases as increased demand for costly treatments including GLP-1 weight-loss drugs, higher prices from hospitals and other providers, and insurer assumptions that enrollment could decline if premium tax credits expire.
January 01, 2025 high temporal
Reported contributors to rising ACA marketplace premiums.
GLP-1 drugs, including semaglutide formulations marketed as Ozempic and Wegovy, are used both for weight loss and for treatment of type 2 diabetes.
high descriptive
Therapeutic uses of GLP-1 receptor agonist medications.